Liver transplantation in HCV/HIV positive patients

Yasuhiko Sugawara, Sumihito Tamura, Norihiro Kokudo

Abstract
Since the introduction of highly active antiretroviral therapy (HAART) in 1996 for human immunodeficiency virus (HIV)-infected patients, the incidence of liver diseases secondary to co-infection with hepatitis C has increased. Although data on the outcome of liver transplantation in HIV-infected recipients is limited, the overall results to date seem to be comparable to that in non-HIV-infected recipients. Liver transplant centers are now accepting HIV-infected individuals as organ recipients. Post-transplantation HIV replication is controlled by HAART. Hepatitis C re-infection of the liver graft, however, remains an important problem because cirrhotic changes of the liver graft may be more rapid in HIV-infected recipients. Interactions between the HAART components and immunosuppressive drugs influence drug metabolism and therefore meticulous monitoring of drug blood level concentrations is required. The risk of opportunistic infection in HIV-positive transplant patients seems to be similar to that in HIV-negative transplant recipients.

Key words: Hepatitis C virus; Human immunodeficiency virus; Living donor liver transplantation; Interferon; Ribavirin

Peer reviewers: Marcelo AF Ribeiro, Professor, MD, PhD, TCBC, TCBCD, FACS, Department of Surgery, Santo Amaro University, Alameda Gregorio Bogossian Sobrinho, 80 /155, Santana de Parnaiba, SP 06543-385, Brazil; Salvatore Gruttadauria, MD, PhD, Abdominal Transplant Surgery, ISMETT-UPMC, Via E. Tricomi N. 1, Palermo 90127, Italy

Sugawara Y, Tamura S and Kokudo N. Liver transplantation in HCV/HIV positive patients. World J Gastrointest Surg 2011; 3(2): 21-28 Available from: URL: http://www.wjgnet.com/1948-9366/full/v3/i2/21.htm DOI: http://dx.doi.org/10.4240/wjgs.v3.i2.21

INTRODUCTION
Liver transplantation is an established standard therapeutic option for end-stage liver disease (ESLD) with a 1 year survival rate exceeding 80%[1]. Before the introduction of highly active antiretroviral therapy (HAART) in 1996, the results of transplantation for patients with human immunodeficiency virus (HIV) were poor[2-5] and HIV was considered a contraindication in most centers[6-8]. The 3 year survival rates were around 45% and the most frequent cause of death was acquired immune deficiency syndrome (AIDS)[2-3].

Since the introduction of HAART, HIV-related morbidity and mortality have dramatically decreased from 20-30 to 1.5-2.5 per 100 person-years[9,10]. In the setting of the improved prognosis in the HIV-infected population, the focus has turned to the morbidity and mortality associated with hepatitis C (HCV) and ESLD[11-13]. As HAART has changed HIV infection to a chronic condition, transplant centers around the world are slowly becoming less reluctant to accept HIV-positive patients as transplant recipients for both medical and ethical reasons[14-16] and liver transplantation is now considered a possible therapeutic option for these patients. The aim of the present review is to explore the new indications for liver transplantation in HIV/HCV co-infected patients.
Epidemiology of HIV and HAART

An estimated 33 million persons are currently living with HIV infection worldwide, including 16 million women and 2 million children less than 15 years of age. In 2008, 2 million adults and 0.4 million children were newly infected and 2 million died from HIV infection. HIV infection is transmitted via heterosexual contact, intravenous drug use and homosexual contact.

Liver-related diseases among HIV-infected persons are caused by hepatitis B virus and/or HCV co-infection, hepatotoxic medication, alcohol and illegal drug use. Of these, co-infection with HCV is the most frequent cause of liver disease in HIV patients and substantially contributes to morbidity and mortality. HIV and HCV usually share common routes of transmission. Approximately 4 to 5 million HIV-infected persons are co-infected with HCV. The prevalence of co-infection differs by geographical region and by patient demographic and behavioral characteristics ranging from 1%-5% in persons who acquired HIV infection by heterosexual or homosexual contact to 70%-95% in patients with current or former injecting drug use and transfused hemophilia patients.

HCV Management Before Transplantation

There are several challenges in the management of HIV/HCV co-infected patients who require transplantation. The first is to minimize mortality while on the organ transplant waiting list because such patients frequently have a more rapid progression from the first decompensation to death. The interval between the first manifestation of liver decompensation and death is 16 mo for HIV/HVC co-infected versus 48 mo for HIV mono-infected patients. Prognostic factors after first decompensation include age, severity of liver disease [model for end-stage liver disease (MELD) score] and the nature of the decompensation event.

HCV/HIV co-infections adversely affect each other: HIV infection accelerates the progression of HCV disease by increasing HCV viremia, causing cellular immunodeficiency, increasing the risk of liver fibrosis and cirrhosis and leading to the rare fibrosing cholestatic hepatitis. HCV may adversely affect the course of HIV infection by reducing the efficacy of antiretroviral treatment and increasing the rate of antiretroviral medication-related hepatotoxicity. The effect of antiretroviral therapy to reduce liver-related mortality in HCV co-infected persons is controversial. Some co-infected persons are not eligible for HCV treatment due to somatic or psychosocial comorbidities, contraindications for HCV drugs and decompensated cirrhosis.

Indications for Transplantation

Table 1 showed the inclusion criteria for liver transplantation. The acceptance criteria for liver transplantation in HIV-positive recipients continue to evolve with increased experience with the co-infected population. In deceased donor liver transplantation, there are ethical concerns regarding the use of a scarce resource for a group of recipients with unknown survival duration. The acceptance criteria have gradually expanded, however, based on acceptable initial results.

The best timing for liver transplantation from the point of view of liver damage (Child-Pugh or MELD) is unknown. Pre-transplant survival for liver candidates is reported to be poorer in HIV-infected individuals compared with others awaiting liver transplantation, despite equivalent MELD scores. In one study, significantly fewer HIV patients (26% of 58) survived on a liver transplant waiting list compared to candidates without HIV (63% of 860). Although more rapid deterioration in HIV co-infected patients may be the cause, death in that study was not associated with MELD, viral load, CD4, ability to tolerate medications or HCV progression. Further studies are necessary to understand the risk factors for death in HIV-positive patients on the liver transplant waiting list.

The inclusion criteria of an NIH sponsored study in the USA are AIDS-related opportunistic infections or cancers that are resolved by sufficient treatment prior to transplant. CD4 counts should be greater than 100/mL for those without a history of opportunistic infection and greater than 200/mL for those with a history of opportunistic infection completely treated before transplantation. These requirements may be applied 3 to 4 mo prior to transplantation. Opportunistic infections include chronic cryptosporidiosis, progressive multifocal leukoencephalopathy and multi-drug resistant systemic fungal infections. Patients with a history of AIDS-associated lymphoma should be excluded. Most clinical trials include individuals with a history of resolved cutaneous Kaposi’s sarcoma if a recent high-resolution computed tomography scan reveals no evidence of pulmonary lesions.

In a Spanish consensus statement, the criteria are similar except for the requirement of CD4 cell counts greater than 350/mL in patients that do not fulfill the HAART criteria. Ragni et al. noted that cumulative survival among HIV-positive recipients is similar to that of age- and race-comparable HIV-negative recipients.

Another potential conflict regarding the absolute requirement for a CD4 cell count greater than 350/mL in patients that do not fulfill the HAART criteria. Ragni et al. noted that cumulative survival among HIV-positive recipients is similar to that of age- and race-comparable HIV-negative recipients.

Unfortunately, however, most recipients cannot tolerate HAART therapy due to its hepatotoxicity. When an undetectable HIV viral load is not achievable, an experienced HIV clinician should predict the ability to...
control HIV after the transplantation, based on a complete review of the antiretroviral history, HIV RNA history and resistance testing. This issue is more controversial for patients with CD4 counts greater than 100/mL but who have detectable HIV that is multi-drug-resistant. Currently, most centers still consider this an exclusion criterion, although with more data demonstrating the safety of immunosuppression in the HIV-positive patient as well as an increasing number of antiretroviral agents, this exclusion criterion may be liberalized on a case by case basis.

**SURGICAL RESULTS**

**Survival**

Survival at 1 year post-transplantation ranges from 58% to 89% (Table 2). Ragni et al. reported 1, 2 and 3 year survival rates of 87%, 73% and 73% in 24 HIV-positive patients which were not statistically different from age and race-matched HIV-negative patients. Similar results were reported based on an analysis of 15 HIV-positive recipients with a 3 year survival rate of 73% compared to 79% for HIV-negative recipients. Neff et al. reported that graft and patient survival rates in HIV-positive patients are similar to that of HIV-negative patients transplanted for the same indication. Studies that analyzed liver transplantation for a variety of reasons showed excellent outcome for ESLD irrespective of underlying HIV infection. Another report showed lower survival rates in 27 patients with 1, 3 and 5 year survival rates of 67%, 56% and 33% respectively. A Spanish series found HIV-positive patient survival rates of 90% at 1 year and 67% at 3 years.

Two recently published studies comparing survival in HCV/HIV-co-infected and HCV-mono-infected transplant recipients reported a significantly lower survival rate in co-infected patients. In a French study of 35 HCV/HIV-infected and 44 HCV-infected recipients, 2 and 5 year patient survival rates were statistically lower in co-infected patients, 73% vs 91% and 51% vs 81% respectively. MELD was the only significant predictor for mortality and HIV infection did not predict survival. In a US study of 27 HCV/HIV-infected and 41 HCV-infected recipients, the 3 and 5 year patient survival rates tended to be lower in co-infected patients, 56% vs 72% and 33% vs 72% respectively.

In a review of the United Network for Organ Sharing liver transplant database (between 1997 and 2006), the 2 and 3 year survival rates in 138 HIV-positive recipients were 70% and 66% respectively. These outcomes were slightly worse than the 2 and 3 year survival rates of 81% and 77% respectively of the 30,520 HIV-negative recipients (P < 0.05). The overall results of liver transplantation in HIV-positive patients are favorable but large prospective clinical trials providing insight into survival and clinical management are required.

**Complications**

Rejection episode rates in HIV-positive recipients are not different from those of HIV-negative recipients. HIV-associated opportunistic infections and AIDS-related diseases are uncommon. Only a single case of Kaposi’s sarcoma and multicentric Castleman’s disease has been reported. Death from infectious complications, however, is reported to be more frequent in HIV-positive recipients. Importantly, no HIV disease progression has been reported and HIV replication is efficiently controlled by HAART. An exception, though, is the report by Schreibman et al. that HIV-infected patients experienced significantly higher mortality from infectious complications (4 of 15 recipients). The results of HCC cases within Milan-criteria are encouraging and there are no reports of recurrences.

**Prognostic factors**

A recent report identified high MELD scores at the time of transplant as predictive of a poor outcome. Early and severe HCV graft re-infection is a major determinant influencing post-transplant outcome. Another report showed that HAART intolerance is a significant predictor. Other risk factors include low pre-transplant body mass index and African American race.

**POSTOPERATIVE MANAGEMENT**

**Immunosuppression and HAART**

Cyclosporine (CyA) inhibits CD4 cell apoptosis and...
Table 2  Survival, hepatitis C virus recurrence, and therapy in hepatitis C virus/human immunodeficiency virus co-infected liver transplant patients

| References | Institution | Years | Genotypes | Time to recurrence (mo) | IFN and RBV doses | Time to therapy (mo) | SVR (%) | FCH (n) | Death (n) | Follow up (mo) |
|------------|-------------|-------|------------|-------------------------|-----------------|---------------------|---------|---------|-----------|--------------|
| Prchalish 2001[49], Norris 2004[52] | King’s College | 95-03 | 7 | NA | 5 | From 2 wk: IFN, 3 MU | NA | 0 | 2 | 5 | 12 |
| Rafeceas 2004[53] | Hospital Universitari de Bellvitge | 02-03 | 4, 1b, 1b, 1a | 7 | NA | NA | 1-6 | 0 | 1 | 1 | 14-18 |
| Moreno 2005[54] | Hospital Ramen (Madrid) | 02-03 | NA | 1-6 | NA | NA | 1-6 | 0 | 1 | 1 | 14-18 |
| Radecce 2007[55] | Hospital Eisen | 98-01 | NA | 3-8 | NA | NA | NA | 1 | 2 | 10-61 |
| Vogel 2005[56] | Bonn University | 02-04 | 1a (n = 2), 2a, 2c, 3a | 1-8 | NA | NA | 5-15 | 50 | 0 | 0 | NA |
| Neff 2005[57], Fung 2006[58], de Vera 2006[59] | Thomas E Starzl Transplantation Institute | 97-05 | 27 1 (n = 16), 2 (n = 2), 3 (n = 1) | 6 | IFN and Peg-IFN, RBV 800 μg/d | 2-50 | 27 | 6 | 14 | 27+5 |
| Castells 2007[60] | Hospital Universitari Vall d’Hebron (Barcelona) | 02-05 | 9 1 (n = 7), 3 (n = 2) | 3+3 | Peg-IFN 1.5 μg/kg, RBV 800-1000 mg/d | NA | 14 | 0 | 1 | 15+13 |
| Schreiban 2007[61], Vernarecci 2007[62] | University of Miami | 99-06 | 8 | NA | NA | NA | NA | 25 | 0 | 2 | 6-74 |
| Wojcik 2007[63] | Regina Elena Cancer Institute (Rome) | 02-06 | 10 | NA | NA | NA | NA | 10 | 3 | 6 | 5-46 |
| Duclos-Vallee 2008[64], 2008[65] | Medical University of Lodz (Poland) | 97-06 | 4 1a (n = 2), 2a, 3a | 1-3 | Peg-IFN 180 μg/wk, RBV 200-1000 mg/d | 1-3 | 100 | 0 | 0 | 21-54 |
| Stock 2008[66], Roland 2008[67] | Paul Brouse | 99-05 | 35 1 (n = 20), 2 (n = 1), 3 (n = 9), 4 (n = 4) | 0-3 | Peg-IFN 50-180 μg/wk, and RBV 400-800 mg/d | 0-3 | 16 | 3 | 13 | 44+83 |
| Testillano 2009[68] | University of California, San Francisco | 00-03 | 6 | NA | 1-11 | NA | 1-11 | NA | 2 | 4 | NA |
| Hughes 2010[69] | Hospital de Cruces (Vizcaya) | 01-07 | 12 1 (n = 8), 3 (n = 4) | NA | NA | NA | NA | 50 | 2 | 4 | NA |
| Di Benedetto 2009[70], 2010[71] | Emory University School of Medicine | 03- | 13 1 (n = 3), 3a (n = 7), 4 (n = 3) | 2-16 | Peg-IFN 50-180 μg/wk, and RBV 400-800 mg/d | NA | 0 | 2 | 4 | 1-14 |

HCV: hepatitis C; IFN: interferon; Peg-IFN: pegylated interferon; RBV: ribavirin; SVR: sustained virological response; NA: not available; FCH: fibrosing cholestatic hepatitis.

p55Gag processing by binding to cyclophilin A[60-62]. Some beneficial effects of the combination of HAART and CyA have been demonstrated[83] but low-dose CyA exhibits no benefits in patients with stable early HIV disease[84].

Mycophenolate mofetil (MMF) inhibits inosine monophosphate dehydrogenase and depletes the pool of deoxyguanosine triphosphate. MMF is expected to reduce HIV infection by both virological and immunological mechanisms[85-70]. Antagonism due to the inhibition of thymidine kinase has been reported with MMF plus the thymidine analogues zidovudine and stavudine. Mitochondrial toxicity of nucleoside reverse transcriptase inhibitors (NRTI) is potentially augmented by the effect of MMF. Mitochondrial toxicity and lactic acidosis are linked to the use of didanosine, stavudine and zalcitabine and are attributed to damage to mitochondrial polymerase[71].

Sirolimus (SRL) downregulates the expression of chemokine receptor 5 on T-cells which is required for the propagation of macrophage tropic strains of HIV-1[72]. SRL inhibits the progression of Kaposi’s sarcoma and primary effusion lymphoma[86-73].

Interactions between HAART drugs [protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs)] and calcineurin inhibitors or SRL are well described[74,75]. NNRTIs induce the expression of cytochrome P450, family A gene (CYP3A)[76]. PIs inhibit the production of cytochrome P450 enzymes or P-glycoprotein. CyA, tacrolimus and SRL are substrates of CYP3A4 and P-glycoprotein. PIs, therefore, increase
blood levels of CyA, tacrolimus and SRL, requiring dose reductions of 85% to 99% (Table 2). HAART without PIs may have fewer significant interactions with CyA, tacrolimus and SRL.

Efavirenz (NNRTI) induces the production cytochrome P450 enzymes but when efavirenz or a nucleoside analogue combination are added to the treatment regimen, little change in the dosing of tacrolimus is required. In contrast, nelfinavir and lopinavir/ritonavir inhibit the first pass metabolism of tacrolimus, resulting in an increase in its elimination half-life and a reduction in its oral clearance.

Monitoring for HAART-associated hepatotoxicity is important. The use of NRTIs is associated with hepatic steatosis, mitochondrial dysfunction and fulminant hepatic failure. PI-related hepatitis occurs in 5% to 9% of patients and has an aggressive course in HCV-positive patients. Liver dysfunction is observed in up to 30% of patients taking NNRTIs. A French study reported evidence of mitochondrial dysfunction in 5 patients with severe recurrent HCV, with most patients developing mitochondrial dysfunction while on stavudine or stavudine plus didanosine and in patients concurrently using ribavirin.

To maintain virological control of HIV infection, quantitative HIV RNA and CD4 cell counts should be measured with the first assays at 1 mo after transplant and subsequent studies every 2 to 3 mo thereafter. If patients have persistent HIV viremia, resistance testing should be performed to determine treatment options.

HCV management

HCV recurrence is a significant problem following transplantation, although there are reports of spontaneous clearance of HCV post-transplantation. HCV recurrence appears earlier in HIV-infected HCV patients than in HIV-uninfected HCV patients (median time 2 mo) and the rate of the progression of fibrosis is enhanced. In one controlled study, the proportion of patients with bridging fibrosis or cirrhosis at 2 and 5 years post-transplantation was 28% and 48% respectively for HCV-HIV co-infected patients versus 10% and 18% respectively in HCV-mono-infected patients. HCV recurrence is attributed to graft loss (Table 2). The prognosis for patients with fibrosing cholestatic hepatitis is poor.

Pegylated interferon and ribavirin combination therapy is the mainstay for the management of recurrent HCV disease. The mitochondrial toxicity of HAART, however, increases when used in conjunction with ribavirin. The rates of a sustained virological response (SVR) are low in co-infected patients, apart from one recent study that showed 100% SVR. SVR occurs in only 11% to 27% of treated patients (Table 2). Biochemical responses are obtained in more than half of patients but histological stabilization or improvement is rare in virological non-responders. Tolerability of the full dose therapy is limited, contributing to the poor SVR rates.

In the HCV-mono-infected population, viral factors (a high viral load before and after transplantation) and host factors (donor age > 50 years) are associated with a more severe recurrence of HCV. Corticosteroid boluses are also associated with a severe HCV recurrence and should be avoided. Rapid corticosteroid withdrawal after transplantation should be avoided and may be associated with a more rapid progression of fibrosis. The effects of immunosuppressant agents, including tacrolimus, CyA, MMF, anti-interleukin 2 receptor antibodies, SRL and azathioprine, on the severity of HCV recurrence are controversial.

Prophylaxis for opportunistic infections

The risk of opportunistic infection in HIV-positive transplant patients seems to be similar to that of HIV-negative transplants. The ability to suppress HIV viral loads in patients on HAART is associated with the stabilization of, or improvement in, CD4 counts, which decreases opportunistic infection in HIV-positive patients.

Prophylactic regimens for preventing opportunistic infection include those against Pneumocystis jiroveci with trimethoprim-sulfamethoxazole, toxoplasmosis (for CD4 counts < 100), Mycobacterium avium complex (for CD4 counts < 50) and histoplasmosis and coccidioidomycosis. For patients at risk for primary toxoplasmosis due to donor infection, trimethoprim-sulfamethoxazole should be considered for primary prevention; dapsone or atovaquone in combination with pyrimethamine can be considered for patients intolerant to trimethoprim-sulfamethoxazole.

CONCLUSION

Clinical trials suggest that liver transplantation in HIV/HCV co-infected patients is safe and that HIV infection does not influence the outcome. The United Network for Organ Sharing no longer considers HIV an absolute contraindication for transplantation. The French agency for Organ Distribution has also concluded that there is no reason to consider HIV a contraindication. Spain has published a national policy advocating liver transplantation for patients with HIV infection within defined criteria.

To improve the results of liver transplantation in HIV-infected individuals, better selection of candidates at an earlier stage of liver disease and optimization of donor and perioperative factors are needed. The natural history of HCV re-infection and treatment algorithms must also be determined as HCV recurrence is the most important concern. Better management of HAART after transplantation is also required.

REFERENCES

1. Adam R, Lucidi V, Karam V. Liver transplantation in Europe: is there a room for improvement? J Hepatol 2005; 42: 33-40

2. Gordon FH, Mistry PK, Sabin CA, Lee CA. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998; 42: 744-749

3. Bouscarat F, Samuel D, Simon F, Debat P, Bismuth H, Saimot
Sugawara Y et al. Liver transplantation for HIV/HCV

AG. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1. Clin Infect Dis 1994; 19: 854-859

4 Erice A, Rhame FS, Heussen ST, Dunn DL, Balfour HH, Jr. Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. Rev Infect Dis 1991; 13: 537-547

5 Tzakis AG, Cooper MH, Dummer JS, Ragni M, Ward JW, Starzl TE. Transplantation in HIV+ patients. Transplantation 1990; 49: 354-358

6 Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of U.S. transplant centers. Transplantation 1998; 65: 1187-1191

7 Rubin RH, Tolkoff-Rubin NE. The problem of human immunodeficiency virus (HIV) infection and transplantation. Transplant Int 1988; 1: 36-42

8 Mullen MA, Kohut N, Sam M, Blends L, Singer PA. Access to adult liver transplantation in Canada: a survey and ethical analysis. CMAJ 1996; 154: 337-342

9 Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Furher J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860

10 Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, Weid B, Akerlund B, Calvo M, Montforte A, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-1641

11 Rosenthal E, Paloux G, Bernard N, Pradier C, Roy D, Bentata M, Michelet C, Pol S, Perronne C, Cabouc P. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GEMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007; 14: 183-188

12 Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snyderman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-497

13 Thio CL, Sebag EC, Skolsky R, Jr., Phair J, Visscher B, Munoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926

14 Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, Dusheiko GM, Lee CA, Ludlam CA, Preston FE. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors’ Organisation. Lancet 1997; 350: 1425-1431

15 Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, Benhamou JP, Erlinger S, Valla D, Marcellin P. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29: 1306-1310

16 Halpern SD, Tzakis AG, Dummer JS, Siddappa N, Nalesnik MA. Solid-organ transplantation in HIV-infected patients. N Engl J Med 2002; 347: 284-287

17 Halpern SD, Schels DA, Shaked A, Stock PG, Blumberg E. Determinants of transplant surgeons’ willingness to provide organs to patients infected with HBV, HCV or HIV. Am J Transplant 2005; 5: 1319-1325

18 Roland MO, Le Bo, Braff J, Stock PG. Key clinical, ethical, and policy issues in the evaluation of the safety and effectiveness of solid organ transplantation in HIV-infected patients. Arch Intern Med 2003; 163: 1773-1778

19 Roland MO, Hamid K, Devereux DW. Responding to organ failure in HIV-infected patients. N Engl J Med 2003; 348: 2279-2281

20 UNAIDS/WHO. Global summary of HIV/AIDS epidemic, December 2008 Available from: URL: http://www.who.int/hiv/data/2009_global_summary.pdf assessed August 27, 2010

21 Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: S6-S9

22 Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med 2007; 356: 1445-1454

23 Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001; 183: 1112-1115

24 Polard E, Camus C, Abaute BY, Turlin B, Arvieux C, Messmer M, Allain H, Boudjema K. Retransplantation for acute liver failure due to combined antiviral agents in an HIV-HCV coinfected liver transplant recipient. Transplantation 2005; 80: 1136-1138

25 Valtell-Pichard A, Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. J Hepatol 2006; 44: S28-S34

26 Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, Reiss P, Thielbaut R, Weiland O, Yazdanpanah Y, Zeeuwm S. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 615-624

27 Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 992-1002

28 Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti JC, Hirschel B, Janin P, Francisci P, Fehr M, Telenzi A. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800-1805

29 den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM. Hepatitis B and C virus co-infection and the risk of hepatotoxicity of highly active antiretroviral therapy. J Hepatol 2003; 39: 773-778

30 Zinkernagel AS, von Wyl V, Ledergerber B, Ribberet M, Furrer H, Battegay M, Hirschel B, Tarr PE, Opravil M, Bernasconi E, Schmid P, Weber R. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antivir Ther 2000; 5: 111-134

31 Ragni MV, Belle SH, Im K, Neff G, Roland M, Stock P, Heaton N, Humar A, Fung JF. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 1412-1420

32 Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, Shahil O, Fung JJ. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9: 239-247

33 Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, Terrault NA, Frassetto LA, Palefsky JM, Tomlanovich SJ, Ascher NL. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003; 76: 570-575

34 de Vera ME, Dworchick I, Tom K, Eghtesad B, Thai N, Shahil O, Marcos A, DeMetriss A, Jain A, Fung JJ, Ragni MV. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6: 2983-2993

35 Ragni MV, Eghtesad B, Schlesinger KW, Dworchick I, Fung JJ,
of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. [Acquir Immune Defic Syndr] 1999; 21: 362-370

69 Heredia A, Margolis D, Oldach D, Hazen R, Le N, Redfield R, Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. [Acquir Immune Defic Syndr] 1999; 22: 406-407

70 Coull JJ, Turner D, Melby T, Betts MR, Lanier R, Margolis DM. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. [Acquir Immune Defic Syndr] 2001; 26: 423-434

71 Fung J, Eghtesad B, Patel-Tom K, DeVera M, Chapman H, Ragi M. Liver transplantation in patients with HIV infection. [Liver Transpl] 2004; 10: S39-S53

72 Heredia A, Amoroso A, Davis C, Le N, Reardon E, Dominique JK, Klingebiel E, Gallo RC, Redfield RR. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. [Proc Natl Acad Sci USA] 2003; 100: 10411-10416

73 Sin SH, Roy D, Wang L, Staudt MR, Fakhari FD, Patel DD, Henry D, Harrington WJ Jr., Damania BA, Dittmer DP. Rapamycin is efficacious for primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. [Blood] 2007; 109: 2165-2173

74 Frassetto L, Baluom M, Jacobsen W, Christians U, Roland ME, Stok PG, Carlson L, Benet LZ. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. [Transplantation] 2005; 80: 13-17

75 Teicher E, Vincent I, Bonhomme-Faivre L, Abbara C, Barrail A, Boissonnas A, Duclos-Valle JC, Taburet AM, Samuel D, Vittecoq D. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV coinfected liver transplant recipients in the ANRS HC-08 study. [Clin Pharmacokinet] 2007; 46: 941-952

76 Shekik AM, Wolf DC, Lebovics E, Goldberg R, Horowitz HW. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. [Transplantation] 1999; 68: 307-309

77 Vogel M, Voigt E, Michaelis HC, Sudhop T, Wolff M, Turler A, Sauerbruch T, Rockstroh JK, Spengler U. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. [Liver Transpl] 2004; 10: 939-944

78 Jain AK, Venkataramanan R, Shapiro R, Sclantebury VP, Potdar S, Bonham CA, Pokharna R, Rohal S, Ragi M, Fung JJ. Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients. [Transplant Proc] 2002; 34: 1540-1541

79 Izzedine H, Launay-Vacher V, Baumelou A, Deray G. Antiretroviral and immunosuppressive drug-drug interactions: an update. [Kidney Int] 2004; 66: 532-541

80 Chariot P, Droguet I, de Lacroix-Smamia I, Eliezer-Vanerot MC, Chazaud B, Lombs A, Schaeffer A, Zafraen FS. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. [Hepatol] 1999; 30: 156-160

81 Lai KK, Gang DL, Zachawi JK, Cooley TP. Fulminant hepatic failure associated with 2’,3’-dideoxynosine (ddI). [Amm Intern Med] 1991; 115: 283-284

82 Arrilbas Jr, Ibarra C, Ruiz-Antonar B, Pena JM, Esteban-Calvo C, Frias J, Vazquez JJ, Gonzalez-Garcia JJ. Acute hepatitis in HIV-infected patients during ritonavir treatment. [AIDS] 1998; 12: 1722-1724

83 Sulkowsky MS, Thomas DL, Chaissin RE, Moore RD. Elevated liver enzymes following initiation of antiretroviral therapy. [JAMA] 2000; 283: 2526-2567

84 Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceda A, Marcos MA, Milinkovic A, Garcia-Varo MA, Mallolas J, Carne X, Phillips A, Gattell J. Hepatotoxicity in HIV-infected patients receiving nevirapine-containing antiretroviral therapy. [AIDS] 2001; 15: 1261-1268

85 Bhagat V, Foont JA, Schiff ER, Regev A. Spontaneous clearance of hepatitis C virus after liver transplantation in two patients coinfected with hepatitis C virus and human immunodeficiency virus. [Liver Transpl] 2008; 14: 92-95

86 Lefeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with rifabulin in HIV/HCV coinfected. [Lancet] 2001; 357: 280-281

87 Antoniades C, Macdonald C, Kinesley A, Taylor C, Norris S. Mitochondrial toxicity associated with HAART following liver transplantation in an HIV-infected recipient. [Liver Transpl] 2004; 10: 699-702

88 Wojcik K, Vogel M, Voigt E, Speidel N, Kalff JC, Goldmann G, Oldenburg J, Sauerbruch T, Rockstroh JK, Spengler U. Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Born cohort. [Aids] 2007; 21: 1363-1365

89 Castells L, Esteban JI, Bilbao I, Vargas V, Allende H, Ribera E, Piron M, Sauleda S, Len O, Pahissa A, Esteban R, Guardia J, Margarit C. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients. [Anticiv Th Secret] 2006; 11: 1061-1070

90 Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. [J Viril Hepat] 2007; 14 Suppl 1: 89-96

91 Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. [Liver Transpl] 2007; 13: 21-29

92 Price P, Mathiot N, Krueger R, Stone S, Keane NM, French MA. Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. [J Clin Viro] 2001; 22: 279-287

93 Samuel D, Duclos Valee JC, Teicher E, Vittecoq D. Liver transplantation in patients with HIV infection. [Hepatol] 2003; 39: 3-6

94 Solid Organ Transplantation in HIV: Multi-Site Study Version 7.0, July 2009. Available from: URL: http://www.HIVtransplant.com. Accessed August 2010

95 O’Grady J, Taylor C, Brook G. Guidelines for liver transplantation in patients with HIV infection (2005). [HIV Med] 2005; 6 Suppl 2: 149-153

96 Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, Freise CE, Benet LZ, Ascher NL, Roberts JP, Murphy B, Keller MJ, Olinhoff KM, Blumberg EA, Brayman KL, Bartlett ST, Davis CE, McCune JM, Bredt BM, Stablein DM, Stock PG. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. [Am J Transplant] 2008; 8: 355-365

97 Testillano M, Fernandez JR, Suarez MJ, Gastaca M, Bustamante J, Pijoan JJ, Montejo M, Valdivieso A, Ruiz P, Gonzalez J, Ortiz de Urbina J. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center. [Transplant Proc] 2009; 41: 1041-1043

98 Hughes CB, Dickson RC, Krishna M, Willingham DL, Satyanarayana R, Harnois DM, Keaveny AP, Rosser B, Aranda-Michel J, Kramer DJ, Hellinger W, Mendez J. HCV recurrence in HIV-infected patients after liver transplantation. [J Int Assoc Physicians AIDS Care (Chic Ill)] 2010; 9: 87-89

99 Di Benedetto F, Di Sandro S, De Ruvo N, Montalti R, Ballarin R, Guerrini GP, Spaggiari M, Guaraldi G, Gerunda G. First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation. [Transplantation] 2010; 89: 733-738

- Editor Wang JL - Editor Roemmee A - Editor Liu N